font size
Sign in 
When Barack Obama was a junior senator from Illinois he introduced legislation designed to foster the development of personalized medicine. New versions of that bill have followed, but never managed to get out of committee. The latest one, introduced in May, now faces the added dynamic of an emerging controvery over direct-to-consumer genetic tests. We spoke to attorney Dan Vorhaus, editor Genomics Law Report, about the legislative efforts, what this latest version of the bill seeks to accomplish, and whether there’s a future for direct-to-consumer genetic tests. Read More
Government Funding
- Boon for Biodefense
Cellerant and Achaogen rack up millions in new contracts. Read More
Comparative Effectiveness
- Knowing What You Know
Comparative effectiveness research comes to the FDA – but in a good way – sort of. Read More
Deals
- Another Specialty Buy for Pfizer
FoldRX acquisiton adds to neuroscience portfolio. Read More - A Big Bet on Biofuels
Shell and Cosan joint venture moves closer to reality. Read More - Roche Bets Big on Aileron
Partners see promise in peptides for tackling tough diseases. Read More
Drug Development
- Remarkable Result in Melanoma Drug Trial
Study drug shrinks tumors in 81 percent of melanoma patients. Read More
Drug Safety
- Actos and Avandia pose similar risks
New study contrasts with earlier findings on top diabetes drugs. Read More
Chronic Fatigue Syndrome
- Retrovirus Linked to Chronic Fatigue Syndrome
Study could open new avenues of treating a debilitating disease. Read More
Research
- Costs of Scientific Misconduct
Case study sheds light on underappreciated consequences of research misconduct. Read More
Trials and Tribulations
- Abuse Concerns Lead FDA Committee to Reject Expanded Use of Jazz Pharmaceuticals’ Drug
The weekly round-up of failed trials, missed targets and other business mishaps. Read More
- The Burrill Report: (September 7, 2010): DOJ Seeks Stay in Stem Cell Ruling
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
ONLINE POLL
August 27, 2010
How big a set-back to the advancement of regenerative medicine is the recent injunction on federally funded research on human embryonic stem cells?
Now Available
The Burrill Report
August 2010
August 2010
The August issue of The Burrill Report is now available.
Click here to buy.
Podcast
Drug Recalls Soar
Bowman Cox, managing editor for The Gold Sheet, discusses the record number of drug recalls in 2009. Listen Now
.jpg)
.jpg)
By the numbers
Roche Dominates the Deal Flow
The Swiss biopharma announces a new acquisition and a drug discovery partnership.
.jpg)
.jpg)
.gif)
.gif)
.png){kind=small}
- Sanofi Chief Extends Hand to Bypass Genzyme `Brick Wall'
Bloomberg - U.S. Court Rules Against Obama’s Stem Cell Policy
The New York Times - Takeda Says Lifestyle-Disease Drugs Will Drive Growth
Bloomberg - Study Says Brain Trauma Can Mimic Lou Gehrig’s Disease
The New York Times - Two New Paths to the Dream: Regeneration
The New York Times - Medical Device Makers Face Revamped U.S. Rules for Approvals
Bloomberg - Pfizer May Gain as U.S. Devises Speedy Alternative to Animal Safety Tests
Bloomberg - Judge lets Virginia healthcare challenge proceed
Reuters - F.D.A. Clears Way for Embryonic Stem Cell Trial Using Patients
The New York Times - Technologies Help Adult Children Monitor Aging Parents
The New York Times